31 results about "Oxybutynine" patented technology

Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Disclosed combinations include solabegron and oxybutynin. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.

Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Disclosed combinations include solabegron and oxybutynin. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.

A method for producing a patch comprising a support layer and an adhesive agent layer arranged on at least one surface of the support layer, the method comprising:a step A of obtaining an adhesive agent layer composition comprising oxybutynin hydrochloride as a drug, an acrylic-based polymer and / or a rubber-based polymer as an adhesive base agent, liquid paraffin, a sterol, an organic acid, and a tackifier;a step B of heating the adhesive agent layer composition at a temperature in a range from 55 to 70° C. for 1 to 24 hours; anda step C of cooling the heated adhesive agent layer composition to a temperature lower than room temperature at an average rate of temperature drop of 1 to 20° C. / hour, thereby obtaining the adhesive agent layer comprising the drug at a supersaturated concentration in a dissolved form.

Active compound combinations of compounds of group A, particularly opioids such as (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol or a salt thereof with a physiologically tolerated acid, and compounds of group B, particularly anti-muscarine agents such as oxybutynin or a salt thereof with a physiologically tolerated acid suitable for treatment of an increased urge to urinate or urinary incontinence. Related pharmaceutical formulations and methods of treatment of an increased urge to urinate or urinary incontinence are also provided.

The invention relates to the technical field of pharmaceutical preparations, and discloses an oxybutynin transdermal plaster and a preparation method thereof. The transdermal plaster includes a backing layer and a medicated ointment, and the medicated ointment includes the following raw materials in mass percentages: 3-5% of oxybutynin and / or its pharmaceutically acceptable salt, 10-5% of sodium polyacrylate 15%, pre-cross-linked pectin 5‑8%, hypromellose 1‑2%, aluminum glycylate 0.5‑1%, pectinase@ethylcellulose / chitosan microcapsules 1.5‑3.5%, 10-15% of sorbitol, 1-2% of azone lauryl, 10-15% of ethanol, and the balance is water; the pH of the medicated ointment is controlled at 5.0-6.0 by a pH regulator. The oxybutynin transdermal plaster of the present invention has higher air permeability, and can promote the release of oxybutynin by slowly releasing pectinase in the later stage of application, thereby prolonging the duration and duration of the drug effect of the plaster. Application time.

This oxybutynin-containing transdermal absorption preparation is provided with: a support layer which comprises a base fabric and at least a part of which has water-repellent properties; and an adhesive layer which is layered on one surface of the support layer, wherein the adhesive layer contains an adhesive composition that includes oxybutynin or a pharmaceutically acceptable salt thereof, a cholesterol, and a rubber-based adhesive base material. The oxybutynin may be oxybutynin hydrochloride, and the part having water-repellent properties may be formed from a fluorine-containing compound, and the base fabric may be a knitted fabric.

The invention provides oxybutynin hydrochloride osmotic pump controlled release tablets and a preparation method thereof. The controlled release tablets are stable in drug release speed in release media of different pH values, and the oxybutynin hydrochloride osmotic pump controlled release tablets are released in a gastrointestinal environment at a basically constant rate, so that the blood concentration of oxybutynin hydrochloride is constantly maintained in an effective concentration range for a long time, a peak valley phenomenon is avoided, the toxic and side effects are reduced, and the bioavailability can be improved.